All News
Filter News
Found 125 articles
-
MindMed to Present at H.C. Wainwright 2nd Annual Psychedelics Conference
12/1/2021
Mind Medicine today announced that MindMed's Chief Executive Officer, Robert Barrow, will participate in a panel and Company's management will participate in one-on-one investor meetings at the virtual H.C. Wainwright 2nd Annual Psychedelics Conference to be held on Monday, December 6, 2021.
-
MindMed to Present at the Jefferies London Healthcare Conference
11/12/2021
Mind Medicine is pleased to announce that its CEO, Robert Barrow , will be speaking at Jefferies 2021 London Healthcare Conference, taking place on November 16-19
-
MindMed Appoints Dr. Maria Oquendo to its Scientific Advisory Board
11/5/2021
Mind Medicine is pleased to announce the appointment of Maria A. Oquendo , M.D., Ph.D. to its Scientific Advisory Board.
-
MindMed to Present at Web Summit on Future of Mental Health
11/1/2021
Mind Medicine (MindMed) Inc. is pleased to announce that CEO Robert Barrow will be speaking at Web Summit, taking place on November 1-4, 2021 in Lisbon, Portugal .
-
MindMed and Liechti Lab Provide Results from their Psilocybin R&D Collaboration
9/23/2021
Mind Medicine and Liechti Lab is pleased to announce that Dr. Matthias Liechti presented data from several ongoing studies at the INSIGHT Conference in Berlin, Germany
-
MindMed to Present at H.C. Wainwright 23rd Annual Global Investment Conference
9/10/2021
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce that Robert Barrow, Chief Executive Officer of MindMed, will present at the virtual H.C. Wainwright 23rd Annual Global Investment Conference taking place September 13-15, 2021
-
MindMed to Attend 8th Annual "Mobile in Clinical Trials" Conference
9/9/2021
Mind Medicine is pleased to announce that its Chief Medical Officer, Daniel R. Karlin , MD MA, will co-chair the 8th annual Mobile in Clinical Trials Conference , which will be held virtually on September 27, 2021 and is a partner program to the 2021 DPharm Conference.
-
MindMed and BioXcel Therapeutics Publish an International Patent Application Describing a System for Identifying Agitation Episodes
9/2/2021
MindMed (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) (the "Company"), and BioXcel Therapeutics, Inc. ("BioXcel"), announce the publication of BioXcel's International Patent Application No. PCT/US2020/051256 (published as WO2021055595) for detecting and preventing the early onset of agitation in patients predisposed to highly agitated behaviour.
-
CohBar Appoints Carol Nast to Its Board of Directors
8/16/2021
CohBar, Inc., a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced the appointment of Carol Nast as an independent director on the company’s Board, effective August 11, 2021.
-
MindMed Appoints Dr. Robert Dworkin to Scientific Advisory Board
8/10/2021
MindMed (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ), a leading biotech company developing psychedelic-inspired therapies, announces the addition of Robert H. Dworkin, Ph.D. to its Scientific Advisory Board.
-
MindMed Appoints Pharmaceutical Veteran Peter Bergethon, M.D. to Scientific Advisory Board
6/17/2021
MindMed (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, has announced the addition of Dr. Peter Bergethon, a world-leading expert in neurology, digital medicine, and central nervous system (CNS) drug development to the Company's Scientific Advisory Board.
-
MindMed Announces Chief Executive Officer Transition
6/9/2021
Mind Medicine announces that J.R. Rahn, the Company's co-founder and chief executive officer, is stepping down as chief executive officer and a director, and that its chief development officer, Robert Barrow, will assume the position.
-
MindMed and Liechti Lab in Basel Switzerland Publish First Pharmacogenetic Data on LSD to Help Guide Personalized Dosing
5/26/2021
MindMed, a leading psychedelic medicine biotech company, announced the publication of the first pharmacogenetic data on LSD to help personalize dosing.
-
MindMed Announces Launch of Collaboration with Nextage Therapeutics' Brain Targeting Liposome System
5/24/2021
MindMed (NASDAQ: MNMD, NEO: MMED, DE: MMQ), a leading clinical stage psychedelic medicine company, and Nextage Therapeutics (TASE: NXTG), an Israeli innovative drug development company, announce the execution of a Memorandum of Understanding (the "MOU") regarding the launch of an exclusive collaborative development program to optimize the delivery of certain psychedelic drug candidates
-
MindMed Announces the Approval of Mescaline Study
5/20/2021
MindMed, a leading clinical stage psychedelic medicine company, announced the approval by the local Swiss ethics committee of the first clinical trial evaluating the acute effects of different doses of mescaline and the role of the serotonin 5-HT2A receptor in mescaline-induced altered states of consciousness.
-
MindMed Receives FDA Type C Meeting Response for Project Lucy Phase 2b Clinical Trial
5/17/2021
MindMed, a leading clinical stage psychedelic medicine company, announces receipt of Type C Meeting Responses from FDA leading to the finalization of the Company's clinical development approach for Project Lucy by selecting Generalized Anxiety Disorder as an initial indication.
-
MindMed Announces Appointment of Dr. Sarah Y. Vinson as Additional Director
5/14/2021
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) ("MindMed" or the "Company") is pleased to announce that it has appointed Dr. Sarah Y. Vinson as a director of the Company and a member of its audit committee, effective immediately.
-
MindMed Announces 2021 Q1 Financial Results; Cash Balance of $160m USD ($194m CAD) to Execute on Diverse Clinical Pipeline
5/14/2021
Mind Medicine Inc., a leading psychedelic medicine biotech company, has announced its quarterly financial results for the quarter ended March 31, 2021.
-
MindMed Bolsters Management Team, Appoints Peter Mack PhD as Vice President of Pharmaceutical Development
5/13/2021
MindMed, a leading psychedelic-inspired medicine company has appointed Peter Mack PhD as Vice President of Pharmaceutical Development.
-
MindMed Begins Trading on Nasdaq - Apr 27, 2021
4/27/2021
MindMed, a leading psychedelic medicine biotech company, is pleased to announce the start of trading on The Nasdaq Capital Market.